Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Enteris Biopharma Inc","sponsor":"CARA Therapeutics","pharmaFlowCategory":"D","amount":"$13.0 million","upfrontCash":"$8.0 million","newsHeadline":"SWK Holdings\u2019 Subsidiary, Enteris Biopharma, Receives Second Milestone Payment from Cara Therapeutics","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"December 2020","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II"},{"orgOrder":0,"company":"Enteris Biopharma Inc","sponsor":"CARA Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$8.0 million","newsHeadline":"SWK Holdings' Subsidiary, Enteris BioPharma, Receives $10 Million Milestone Payment from Cara Therapeutics","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II"},{"orgOrder":0,"company":"Enteris Biopharma Inc","sponsor":"CARA Therapeutics","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"$5.0 million","newsHeadline":"SWK Holdings' Subsidiary, Enteris BioPharma, Receives $5 Million Milestone Payment from Cara Therapeutics","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"December 2021","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II"},{"orgOrder":0,"company":"Enteris Biopharma Inc","sponsor":"SWK Holdings","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enteris BioPharma Announces Acceptance of Abstract for Oral Presentation at ASRM 2022 Scientific Congress & Expo","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Peptide","productStatus":"Approved","date":"July 2022","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II"},{"orgOrder":0,"company":"Enteris Biopharma Inc","sponsor":"CARA Therapeutics","pharmaFlowCategory":"D","amount":"$46.0 million","upfrontCash":"$8.0 million","newsHeadline":"SWK Holdings' Subsidiary, Enteris BioPharma, Receives $5 Million Milestone Payment from Cara Therapeutics","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Peptide","productStatus":"Approved","date":"October 2022","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II"},{"orgOrder":0,"company":"Enteris Biopharma Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enteris BioPharma Presents Study of Ovarest\u00ae Demonstrating Oral Delivery Comparable to or Exceeding Injectable Leuprolide","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Peptide","productStatus":"Approved","date":"October 2022","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II"}]

    Find Clinical Drug Pipeline Developments & Deals by Enteris Biopharma Inc

    Menu

    Enteris Biopharma Inc

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    EXCIPIENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Enteris Biopharma Inc

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Enteris BioPharma Presents Study of Ovarest® Demonstrating Oral Delivery Comparable to or Exceeding Injectable Leuprolide

              Details:

              Ovarest® (leuprolide) is a gonadotropin-releasing hormone analogue that is used to treat endometriosis and uterine fibroids in women, prostate cancer in men, and central precocious puberty in boys and girls.

              Lead Product(s): Leuprolide Acetate

              Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Ovarest

              Highest Development Status: Phase II Product Type: Peptide

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable October 26, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Enteris Biopharma Inc

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              SWK Holdings' Subsidiary, Enteris BioPharma, Receives $5 Million Milestone Payment from Cara Therapeutics

              Details:

              The milestone payment is related to continued clinical progress of Oral KORSUVA (difelikefalin), which is currently the subject of four separate clinical programs for pruritus in patients with hepatic impairment due to primary biliary cholangitis.

              Lead Product(s): Difelikefalin

              Therapeutic Area: Dermatology Product Name: Korsuva

              Highest Development Status: Phase II Product Type: Peptide

              Partner/Sponsor/Collaborator: CARA Therapeutics

              Deal Size: $46.0 million Upfront Cash: $8.0 million

              Deal Type: Licensing Agreement October 10, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Enteris Biopharma Inc

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Enteris BioPharma Announces Acceptance of Abstract for Oral Presentation at ASRM 2022 Scientific Congress & Expo

              Details:

              Oral administration of Ovarest (leuprolide) offers the potential to better address diseases in which gonadotropin-releasing hormone (GnRH) agonists are known to provide benefit and for which an oral format can improve patient compliance.

              Lead Product(s): Leuprolide Acetate

              Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Ovarest

              Highest Development Status: Phase II Product Type: Peptide

              Partner/Sponsor/Collaborator: SWK Holdings

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable July 14, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Enteris Biopharma Inc

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              SWK Holdings' Subsidiary, Enteris BioPharma, Receives $5 Million Milestone Payment from Cara Therapeutics

              Details:

              Enteris is eligible to receive additional potential milestone payments over the next several quarters, subject to the achievement of certain development milestones for Oral KORSUVA, of which Enteris will retain half.

              Lead Product(s): Difelikefalin

              Therapeutic Area: Dermatology Product Name: Korsuva

              Highest Development Status: Phase II Product Type: Peptide

              Partner/Sponsor/Collaborator: CARA Therapeutics

              Deal Size: $25.0 million Upfront Cash: $5.0 million

              Deal Type: Licensing Agreement December 09, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Enteris Biopharma Inc

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              SWK Holdings' Subsidiary, Enteris BioPharma, Receives $10 Million Milestone Payment from Cara Therapeutics

              Details:

              This milestone payment was triggered by confirmation from Cara of the completion of an End-of-Phase 2 Meeting with the U.S. Food and Drug Administration (FDA) for Oral KORSUVA in patients with non-dialysis dependent (NDD) chronic kidney disease (CKD-aP).

              Lead Product(s): Difelikefalin

              Therapeutic Area: Nephrology Product Name: Korsuva

              Highest Development Status: Phase II Product Type: Peptide

              Partner/Sponsor/Collaborator: CARA Therapeutics

              Deal Size: Undisclosed Upfront Cash: $8.0 million

              Deal Type: Licensing Agreement June 11, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Enteris Biopharma Inc

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              SWK Holdings’ Subsidiary, Enteris Biopharma, Receives Second Milestone Payment from Cara Therapeutics

              Details:

              Enteris BioPharma, received a second milestone payment from Cara Therapeutics (Nasdaq: CARA) related to the license agreement for Peptelligence oral formulation technology utilized in Oral KORSUVA, the oral formulation of Cara’s first-in-class KOR agonist, CR845/difelikefalin.

              Lead Product(s): Difelikefalin

              Therapeutic Area: Dermatology Product Name: Korsuva

              Highest Development Status: Phase II Product Type: Peptide

              Partner/Sponsor/Collaborator: CARA Therapeutics

              Deal Size: $13.0 million Upfront Cash: $8.0 million

              Deal Type: Licensing Agreement December 24, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY